Tirzepatide
Reviewed
Short answer
Tirzepatide is a modified peptide based on a body signal called GIP. Its peptide chain has 39 amino acids.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Mounjaro · Zepbound · GIP/GLP-1 agonist
Part of Metabolic peptide medicines
Compared with Retatrutide
Study and product details
What it is
It also has a fat-like side group attached through a linker. This group helps it bind to albumin, a protein in blood. This helps tirzepatide stay in the body longer. Tirzepatide is the active ingredient in Mounjaro and Zepbound. Approval applies to a specific product, use, finished form, and current label. It does not apply to every item sold under the name tirzepatide.
Type of peptide: GIP and GLP-1 receptor agonist. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Strong: Several reliable sources describe this clearly.
Large studies support blood-sugar and weight findings in the groups studied. FDA separately approved a heart-risk use for Mounjaro in certain adults.
Studies have described how approved products enter and affect the body in detail.
Product labels list major warnings, including boxed warnings. They also explain when the medicine must not be used, precautions, and harmful reactions.
The product is well documented when it is a genuine approved medicine. This does not apply to every compounded or counterfeit (fake) version.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
Mounjaro
August 2026 published label- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Blood-sugar control in defined type 2 diabetes populations. FDA approved a heart-risk reduction use for certain adults with type 2 diabetes on August 27, 2026.
Zepbound
February 2026 published label; August 26, 2026 supplement letter- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Long-term weight management and moderate-to-severe obstructive sleep apnea in defined adults with obesity. An August 26, 2026 FDA supplement added cardiovascular-trial information, not a new use.
- Mounjaro
- Zepbound
- Type 2 diabetes for labeled populations
- Lowering the risk of heart attack, stroke, or cardiovascular death in certain high-risk adults with type 2 diabetes under the August 27, 2026 Mounjaro approval
- Chronic weight management for labeled populations
- Moderate-to-severe obstructive sleep apnea in adults with obesity under the current Zepbound label
What studies found
Mounjaro's August 2026 label covers blood-sugar control in adults and children age 10 or older with type 2 diabetes. It also covers lower risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in high-risk adults with type 2 diabetes. Cardiovascular death means death from heart or blood-vessel disease.
Zepbound's posted February 2026 label covers long-term weight reduction in defined adults and moderate-to-severe obstructive sleep apnea in adults with obesity. An August 26, 2026, FDA letter added cardiovascular trial information and a warning update. It did not add Mounjaro's heart-risk use to Zepbound.
The studies looked at specific groups of people for set periods. SURPASS-2 studied adults with type 2 diabetes for 40 weeks. SURMOUNT-1 studied adults with obesity, or overweight with a related condition, who did not have diabetes, for 72 weeks. These groups, comparisons, results, and study lengths limit each finding.
The evidence does not show that tirzepatide gives everyone the same result. It does not establish a universal “metabolic reset,” longer life, or better athletic performance. Evidence for approved medicines does not make compounded, counterfeit, or research-labeled products equivalent to those medicines.
Which products do these findings apply to?
Mounjaro and Zepbound are separate approved products. Their study results and labels do not apply to every compounded or research-labeled tirzepatide product.
Fact checks
3 statements checked. Read what the results mean.
“Tirzepatide has established human outcome evidence for defined metabolic indications.”
Posted product labels, an August 2026 FDA approval letter, and large randomized trials support specific blood-sugar, weight, and cardiovascular findings in defined populations. The cardiovascular risk-reduction use belongs to Mounjaro.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- The labeled and trial populations, outcomes, comparators, and durations for Mounjaro and Zepbound. Mounjaro's heart-risk use was approved August 27, 2026.
Sources for this fact check (6)
“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”
Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.
Sources for this fact check (2)
“Compounded tirzepatide is equivalent to an approved product.”
FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Compounded or otherwise unapproved tirzepatide compared with approved Mounjaro or Zepbound.
Sources for this fact check (1)
Questions people ask about Tirzepatide
Tirzepatide has a chain of 39 amino acids and a fatty-acid side group. The side group helps it bind to albumin, a protein in blood. A finished Mounjaro or Zepbound product also has inactive ingredients listed in its current FDA label. A product sold only as “tirzepatide” is not automatically the same finished product.
Risks and safety limits
Mounjaro's August 2026 label keeps the boxed warning about thyroid C-cell tumors seen in rats. The human risk is unknown. It also reports temporary worsening of diabetes-related eye disease when blood sugar improves quickly. Other product warnings and precautions still apply. This guide does not recommend a product or give dosing or dose-change instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed .Check the rules for athletes ↗Terms used in the studies
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- agonist
- a substance that activates a receptor
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- outcome
- what the study measured
- indication
- the approved or studied use and patient group
- randomized
- assigned to study groups by chance
- comparator
- the treatment or group used for comparison
Read the sources
Show 8 sources
Review history
Updated the Mounjaro source to its August 2026 label and checked its approved uses and eye warning. Zepbound remains a separate product record.
Checked the posted Mounjaro and Zepbound labels against their August supplement letters and clarified which product has each approved use.
Updated Mounjaro and Zepbound label records, added the Mounjaro heart-risk approval and Zepbound supplement, and linked the FDA structure review.
Expanded product, outcome, and unapproved-version boundaries.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error